NICE and Alexion not budging on Soliris price - patient groups speak out in advance of ruling - decision will set precedent for rare diseases. NICE is on a collision course with a pharma company once ...
The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand. Both Amgen's Bkemv and Teva/Samsung Bioepis' Epysqli ...
As the expiration date on Alexion Pharmaceuticals' patent protections grew closer and competitors began developing their own ...
The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication in adults and ...
For the approximately one-in-twelve Canadians who have a rare disease, more bureaucracy is a matter of life and death ...
This month, Samsung Bioepis announced the European launch of Obodence (60 mg pre-filled syringe) and Xbryk (120 mg vial), ...
Zacks.com on MSN
5 Big Drug Stocks That May Continue to Outperform in 2026
In 2026, J&J expects accelerated growth in the Innovative Medicine segment to be driven by its key products as well as new ...
Zacks Investment Research on MSN
ABBV vs. AZN: Which pharma stock is the better investment now?
AbbVie ABBV and AstraZeneca AZN are both global healthcare companies with diversified drug portfolios. Both companies have ...
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of ...
Omeros transitions from a distressed microcap to a small-cap following a transformative Novo Nordisk deal and FDA approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback